S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54
S&P 500   3,821.55
DOW   30,946.99
QQQ   283.54

BioMarin Pharmaceutical Stock Forecast, Price & News

-1.94 (-2.28%)
(As of 06/28/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.89 million shs
Average Volume
1.30 million shs
Market Capitalization
$15.38 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive BMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

BMRN Stock Forecast (MarketRank)

Overall MarketRank

2.75 out of 5 stars

Medical Sector

53rd out of 1,433 stocks

Pharmaceutical Preparations Industry

18th out of 685 stocks

Analyst Opinion: 4.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
BioMarin Pharmaceutical logo

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Stock News Headlines

BioMarin's Solid Pipeline Bears The First Fruit
Biomarin Pharmaceutical Inc. - Registered Shares
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
$-64.08 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.85 billion
Cash Flow
$0.83 per share
Book Value
$23.26 per share


Free Float
Market Cap
$15.38 billion

Social Links

BioMarin Pharmaceutical Frequently Asked Questions

Should I buy or sell BioMarin Pharmaceutical stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BioMarin Pharmaceutical stock.
View analyst ratings for BioMarin Pharmaceutical
or view top-rated stocks.

What is BioMarin Pharmaceutical's stock price forecast for 2022?

13 analysts have issued 12 month target prices for BioMarin Pharmaceutical's shares. Their BMRN stock forecasts range from $70.00 to $135.00. On average, they predict BioMarin Pharmaceutical's stock price to reach $108.46 in the next year. This suggests a possible upside of 30.4% from the stock's current price.
View analysts' price targets for BioMarin Pharmaceutical
or view top-rated stocks among Wall Street analysts.

How has BioMarin Pharmaceutical's stock price performed in 2022?

BioMarin Pharmaceutical's stock was trading at $88.35 at the start of the year. Since then, BMRN shares have decreased by 5.9% and is now trading at $83.15.
View the best growth stocks for 2022 here

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for BioMarin Pharmaceutical

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its earnings results on Wednesday, April, 27th. The biotechnology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.16. The biotechnology company earned $519.36 million during the quarter, compared to analysts' expectations of $505.11 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 1.36% and a net margin of 2.09%. During the same period in the previous year, the company posted $0.29 EPS.
View BioMarin Pharmaceutical's earnings history

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the following people:
  • Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO (Age 69, Pay $3.67M)
  • Mr. Brian R. Mueller, Exec. VP of Fin. & CFO (Age 48, Pay $1.13M)
  • Dr. C. Greg Guyer Ph.D., CTO and Exec. VP of Global Manufacturing & Technical Operations (Age 60, Pay $1.75M)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 60, Pay $1.2M) (LinkedIn Profile)
  • Dr. Henry J. Fuchs M.D., Ph.D., Pres of Worldwide R&D (Age 64, Pay $1.52M)
  • Ms. Erin Burkhart, Group VP & Chief Accounting Officer
  • Traci McCarty, VP of Investor Relations
  • Mr. George Eric Davis, Exec. VP, Gen. Counsel & Sec. (Age 51) (LinkedIn Profile)
  • Mr. Philip Lo Scalzo, Sr. VP & Chief Compliance Officer
  • Ms. Humaira Serajuddin, Sr. VP & Chief Marketing Officer

What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO?

161 employees have rated BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among BioMarin Pharmaceutical's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.61%), Vanguard Group Inc. (8.92%), Capital Research Global Investors (5.07%), Viking Global Investors LP (2.03%), Palo Alto Investors LP (1.16%) and Clearbridge Investments LLC (1.14%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends for BioMarin Pharmaceutical

Which institutional investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Aviva PLC, Capital Research Global Investors, Clearbridge Investments LLC, First Trust Advisors LP, Renaissance Technologies LLC, Edmond DE Rothschild Holding S.A., Group One Trading L.P., and Palo Alto Investors LP. Company insiders that have sold BioMarin Pharmaceutical company stock in the last two years include Brian Mueller, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Richard A Meier, and V Bryan Lawlis.
View insider buying and selling activity for BioMarin Pharmaceutical
or view top insider-selling stocks.

Which institutional investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Fiera Capital Corp, Polar Capital Holdings Plc, National Pension Service, Qube Research & Technologies Ltd, SeaTown Holdings Pte. Ltd., Jennison Associates LLC, and Vanguard Group Inc..
View insider buying and selling activity for BioMarin Pharmaceutical
or or view top insider-buying stocks.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $83.15.

How much money does BioMarin Pharmaceutical make?

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $15.38 billion and generates $1.85 billion in revenue each year. The biotechnology company earns $-64.08 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does BioMarin Pharmaceutical have?

BioMarin Pharmaceutical employs 3,045 workers across the globe.

When was BioMarin Pharmaceutical founded?

BioMarin Pharmaceutical was founded in 1997.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for BioMarin Pharmaceutical is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at [email protected], or via fax at 415-382-7889.

This page (NASDAQ:BMRN) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.